755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICSPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2013Cited by 24
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, Maria Grazia Rumi et al.|Digestive and Liver Disease|2014Cited by 23
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDYPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2012Cited by 10
T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European studyPietro Lampertico, M. Colombo, R. Soffredini et al.|Digestive and Liver Disease|2013Cited by 6
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter studyPietro Lampertico, Massimo Colombo, Mauro Viganò et al.|F1000Research|2012Cited by 3